Aratana Therapeutics to Report Fourth Quarter and Full Year 2015 Financial Results

LEAWOOD, Kan., Feb. 23, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Tuesday, March 15, 2016 at 8:30 a.m. ET to discuss financial results for the fourth quarter ending December 31, 2015 and the full year.

Interested participants and investors may access the audio webcast or use the conference call dial-in:  
     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada
     1 (412) 902-4210 (International)

A replay of the fourth quarter and full year results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10081823: 
     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts 
For investor inquiries: 
Craig Tooman
ctooman@aratana.com 
(913) 353-1026

For media inquiries: 
Rachel Reiff
rreiff@aratana.com 
(913) 353-1050

 

SOURCE Aratana Therapeutics, Inc.